248 related articles for article (PubMed ID: 29051065)
1. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
[TBL] [Abstract][Full Text] [Related]
2. A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
Albrecht D; Iwashima M; Dillon D; Harris S; Levy J
Headache; 2020 Apr; 60(4):701-712. PubMed ID: 31985049
[TBL] [Abstract][Full Text] [Related]
3. Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films.
Esim O; Ozkan CK; Kurbanoglu S; Arslan A; Tas C; Savaser A; Ozkan SA; Ozkan Y
Drug Dev Ind Pharm; 2019 Jun; 45(6):914-921. PubMed ID: 30714426
[TBL] [Abstract][Full Text] [Related]
4. Orally inhaled dihydroergotamine: a review.
Tepper SJ
Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
Saper JR; Silberstein S
Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
[TBL] [Abstract][Full Text] [Related]
6. STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a I123 Precision Olfactory Delivery (POD
Shrewsbury SB; Jeleva M; Satterly KH; Lickliter J; Hoekman J
Headache; 2019 Mar; 59(3):394-409. PubMed ID: 30659611
[TBL] [Abstract][Full Text] [Related]
7. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
Silberstein SD; Shrewsbury SB; Hoekman J
Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
[TBL] [Abstract][Full Text] [Related]
8. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler.
Shrewsbury SB; Cook RO; Taylor G; Edwards C; Ramadan NM
Headache; 2008 Mar; 48(3):355-67. PubMed ID: 18179563
[TBL] [Abstract][Full Text] [Related]
9. Human pharmacokinetics of dihydroergotamine administered by nasal spray.
Humbert H; Cabiac MD; Dubray C; Lavène D
Clin Pharmacol Ther; 1996 Sep; 60(3):265-75. PubMed ID: 8841149
[TBL] [Abstract][Full Text] [Related]
10. Dihydroergotamine nasal spray in the treatment of acute migraine.
Treves TA; Kuritzky A; Hering R; Korczyn AD
Headache; 1998 Sep; 38(8):614-7. PubMed ID: 11398305
[TBL] [Abstract][Full Text] [Related]
11. Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE).
Rothrock JF
Headache; 2007 May; 47(5):740. PubMed ID: 17501862
[No Abstract] [Full Text] [Related]
12. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
Silberstein SD; Kori SH
CNS Drugs; 2013 May; 27(5):385-94. PubMed ID: 23620146
[TBL] [Abstract][Full Text] [Related]
13. Dosing and administration of ergotamine tartrate and dihydroergotamine.
Mathew NT
Headache; 1997; 37 Suppl 1():S26-32. PubMed ID: 9009471
[TBL] [Abstract][Full Text] [Related]
14. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
[TBL] [Abstract][Full Text] [Related]
15. [Migraine: dihydroergotamine nasal spray--an alternative].
Beubler E
Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
[TBL] [Abstract][Full Text] [Related]
16. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
Shrewsbury SB; Kori SH; Miller SD; Pedinoff A; Weinstein S
Curr Med Res Opin; 2008 Jul; 24(7):1977-85. PubMed ID: 18534051
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Aurora SK; Rozen TD; Kori SH; Shrewsbury SB
Headache; 2009 Jun; 49(6):826-37. PubMed ID: 19545249
[TBL] [Abstract][Full Text] [Related]
19. Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults.
Silvestro M; Orologio I; Tessitore A; Trojsi F; Tedeschi G; Russo A
Expert Rev Neurother; 2024 Jun; 24(6):555-564. PubMed ID: 38655598
[TBL] [Abstract][Full Text] [Related]
20. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
